Skip to main content

Table 5 ICER of goserelin vs. chemotherapy in the adjuvant treatment of breast cancer

From: Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer

  ΣQALY ΣCost ICERa
Goserelin vs. Chemotherapy
  SG VS BSA 1.5 m2 BSA 1.8 m2 SG VS
      BSA 1.5 m2 BSA 1.8 m2 BSA 1.5 m2 BSA 1.8 m2
Goserelin 8.81 8.78 5,532      
Chemotherapy         
   CMF 6.83 7.14 1,789 1,792 1,891 1,887 2,283 2,279
   FEC 6.83 7.14 3,606 3,610 974 971 1,176 1,172
   TE 6.83 7.14 12,453 13,785 -3,495 -4,168 -4,220 -5,032
   TEC 6.83 7.14 12,517 13,849 -3,528 -4,200 -4,259 -5,071
  1. aICER = (cost goserelin - cost chemothreapy )/(QALY goserelin - QALY chemothre )
  2. BSA, body surface area; CMF, (cyclophosphamide, methotrexate, 5-fluorouracil); FEC, (5-fluorouracil, epirubicin, cyclophosphamide); TE (docetaxel, epirubicin); TEC, (docetaxel, epirubicin, cyclophosphamide)
  3. Cost in US dollars